최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Tuberculosis and respiratory diseases : TRD = 결핵 및 호흡기 질환, v.65 no.2 = no.283, 2008년, pp.79 - 90
심태선 (울산대학교 의과대학 서울아산병원 호흡기내과) , 고원중 (성균관대학교 의과대학 내과학교실 삼성서울병원 호흡기내과) , 임재준 (서울대학교 의과대학 내과학교실 및 폐 연구소) , 류우진 (결핵연구원)
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
결핵의 과정은? | 결핵은 결핵균에의 노출→감염→발병의 과정을 거친다. 이 과정에서의 감염이란 잠복결핵(latent tuberculosis infection, LTBI), 즉, 살아있는 소수의 균이 체내에 존재하되 | |
현재 결핵에 감염된 전 세계 인구와 환자의 결과는? | 결핵은 특징적으로 접촉(노출)→감염→발병(환자)의 3단계를 거치며 발병한 환자는 다시 다른 사람에게 감염을 일으키는 순환을 반복하면서 전파된다. 현재 전 세계 인 구의 1/3 정도가 감염되어 있는 것으로 추정되고 있는데, 감염된 환자의 대부분(약 90%)은 면역 기전에 의하여 균을 육아종(granuloma) 안에 잘 격리함으로써 발병하지 않고 수명이 다하게 된다. 그러나 약 10% 정도에서는 균이 다시 성장하기 시작하여 발병으로 진행되고 이 중 일부는 전염성을 갖게 된다. | |
결핵 과정에서 감염이란? | 결핵은 결핵균에의 노출→감염→발병의 과정을 거친다. 이 과정에서의 감염이란 잠복결핵(latent tuberculosis infection, LTBI), 즉, 살아있는 소수의 균이 체내에 존재하되 균이 외부로 배출되지도 않고, 증상도 없으며, 방사선학적 검사로도 정상인 경우를 의미한다. 일반적으로 감염자의 약 10%에서 평생의 어느 순간에 결핵이 발병하게 되므로 감염→발병의 과정을 막기 위한 치료를 결핵의 발병을 예방하기 위한 ‘예방화학치료(chemoprophylaxis)’란 용어를 사용하여 왔다. |
?Pediatric Tuberculosis Collaborative Group. Targeted tuberculin skin testing and treatment of latent tuberculosis infection in children and adolescents. Pediatrics 2004;114:S1175-201.
American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep 2000;49:1-51.
Korean Academy of Tuberculosis and Respiratory Diseases. Guideline for the management of tuberculosis. Seoul: Korean Academy of Tuberculosis and Respiratory Diseases; 2005.
National Institute for Health and Clinical Excellence. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London: National Institute for Health and Clinical Excellence; 2006.
Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alphaneutralizing agent. N Engl J Med 2001;345:1098-104.
Korea Food and Drug Administration. Guideline for treatment of latent tuberculosis infection in patients using TNF antagonist. Seoul: Korea Food and Drug Administration; 2004.
Rieder HL. Interventions for tuberculosis control and elimination. Paris: Internatinal Union Against Tuberculosis and Lung Disease; 2002.
International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ 1982;60:555-64.
Ferebee SH, Mount FW. Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. Am Rev Respir Dis 1962;85:490-510.
Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis 1999;3:847-50.
Snider DE Jr, Caras GJ, Koplan JP. Preventive therapy with isoniazid. Cost-effectiveness of different durations of therapy. JAMA 1986;255:1579-83.
Lecoeur HF, Truffot-Pernot C, Grosset JH. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am Rev Respir Dis 1989;140:1189-93.
Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 1992;145:36-41.
Menzies D, Dion MJ, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med 2004;170:445-9.
Haley CA, Stephan S, Vossel LF, Sherfy EA, Laserson KF, Kainer MA. Successful use of rifampicin for Hispanic foreign-born patients with latent tuberculosis infection. Int J Tuberc Lung Dis 2008;12:160-7.
Polesky A, Farber HW, Gottlieb DJ, Park H, Levinson S, O'Connell JJ, et al. Rifampin preventive therapy for tuberculosis in Boston's homeless. Am J Respir Crit Care Med 1996;154:1473-7.
Villarino ME, Ridzon R, Weismuller PC, Elcock M, Maxwell RM, Meador J, et al. Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents. Am J Respir Crit Care Med 1997;155:1735-8.
Davies P, Ormerod P. The role of four months of rifampicin in the treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2005;172:509-10.
Livengood JR, Sigler TG, Foster LR, Bobst JG, Snider DE Jr. Isoniazid-resistant tuberculosis. A community outbreak and report of a rifampin prophylaxis failure. JAMA 1985;253:2847-9.
Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet 1999;353:1843-7.
Reichman LB, Lardizabal A, Hayden CH. Considering the role of four months of rifampin in the treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2004;170:832-5.
Page KR, Sifakis F, Montes de Oca R, Cronin WA, Doherty MC, Federline L, et al. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med 2006;166:1863-70.
Ormerod LP. Rifampicin and isoniazid prophylactic chemotherapy for tuberculosis. Arch Dis Child 1998;78: 169-71.
Whalen CC, Johnson JL, Okwera A, Hom DL, Huebner R, Mugyenyi P, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med 1997;337:801-8.
Ena J, Valls V. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. Clin Infect Dis 2005;40:670-6.
Spyridis NP, Spyridis PG, Gelesme A, Sypsa V, Valianatou M, Metsou F, et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis 2007;45:715-22.
Rennie TW, Bothamley GH, Engova D, Bates IP. Patient choice promotes adherence in preventive treatment for latent tuberculosis. Eur Respir J 2007;30:728-35.
Schechter M, Zajdenverg R, Falco G, Barnes GL, Faulhaber JC, Coberly JS, et al. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. Am J Respir Crit Care Med 2006;173:922-6.
Yun JW, Lim SY, Suh GY, Chung MP, Kim H, Kwon OJ, et al. Diagnosis and treatment of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea. J Korean Med Sci 2007;22:779-83.
Gordin F, Chaisson RE, Matts JP, Miller C, de Lourdes Garcia M, Hafner R, et al. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. JAMA 2000;283:1445-50.
Khan K, Muennig P, Behta M, Zivin JG. Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States. N Engl J Med 2002;347:1850-9.
Centers for Disease Control and Prevention (CDC); American Thoracic Society. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection-- United States, 2003. MMWR Morb Mortal Wkly Rep 2003;52:735-9.
Bergeron KG, Bonebrake RG, Allen C, Gray CJ. Latent tuberculosis in pregnancy: screening and treatment. Curr Womens Health Rep 2003;3:303-8.
Schaaf HS, Gie RP, Kennedy M, Beyers N, Hesseling PB, Donald PR. Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month follow-up. Pediatrics 2002;109:765-71.
Center for Disease Control and Prevention. Managing drug interactions in the treatment of HIV-related tuberculosis. Atlanta: Center for Disease Control and Prevention; 2007.
Wallis RS, Kyambadde P, Johnson JL, Horter L, Kittle R, Pohle M, et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS 2004;18:257-64.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
오픈액세스 학술지에 출판된 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.